Categories Earnings, Health Care

Mallinckrodt soars 10% on strong Q3

Pharmaceutical company Mallinckrodt plc (MNK) Tuesday reported third-quarter results that topped analysts’ estimates, sending its shares up 10% during pre-market hours.

Earnings rose to $113.8 million, or $1.34 per share, from $63.7 million, or $0.66 per share in the year-over period. On an adjusted basis, earnings stood at $2.10 per share, higher than $1.80 per share expected by analysts.

mallinckrodt earnings
Image courtesy: Mallinckrodt

Net sales rose 6.6% to $640 million versus the Street estimate of $633.43.

“Mallinckrodt performed well in the third quarter driven by strong customer demand for our hospital products and effective expense management. This tight expense control also helped us support increased R&D investments in our innovative pipeline,” CEO Mark Trudeau said.

SG&A expenses were $164.0 million or 25.6% of net sales, as compared to $186.3 million, or 31% a year ago.

Eli Lilly tops market estimates; revises guidance

Buoyed by the strong third quarter performance, the UK-based firm raised its adjusted diluted EPS guidance for fiscal 2018 to $7.00 to $7.20.

During Q3, Mallinckrodt also reduced total debt by $170.6 million and ended the quarter with net debt below $6.0 billion.

 

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top